Citizens reiterates Aquestive stock rating on Anaphylm progress
Citizens reiterates Aquestive stock rating on Anaphylm progress
Citizens reiterates Aquestive stock rating on Anaphylm progress
Latest in Markets
-
Dominari Holdings reports 9x return on Cerebras investment
-
UroGen’s UGN-103 shows 94.5% response durability in trial
-
LanzaTech raises $20 million in registered direct offering
-
Form DEF 14C BEASLEY BROADCAST GROUP For: 15 May
-
Tandem Diabetes Care to end employment of chief commercial officer
-
Playtech chairman purchases 57,000 shares for £193,667
Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.